About Occlutech
Occlutech is a company based in Schaffhausen (Switzerland) founded in 2003 by Tor Peters.. Occlutech has raised $70.81 million across 2 funding rounds from investors including Carnegie, Fjarde AP-fonden and unknown. Occlutech has completed 1 acquisition, including NonWoTecc Medical. Occlutech offers products and services including Occluders, ATRIAL FLOW REGULATOR, and Accessories. Occlutech operates in a competitive market with competitors including Xeltis, PECA Labs, Endonovo Therapeutics, Coherex and CoAptus Medical, among others.
- Headquarter Schaffhausen, Switzerland
- Founders Tor Peters
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Occlutech Holding Ag
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$70.81 M (USD)
in 2 rounds
-
Latest Funding Round
$49.19 M (USD), Series C
Dec 21, 2021
-
Investors
Carnegie
& 2 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Occlutech
Occlutech offers a comprehensive portfolio of products and services, including Occluders, ATRIAL FLOW REGULATOR, and Accessories. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Devices for closing heart defects in congenital diseases
Regulator to manage atrial flow and improve heart function
Support tools for cardiac implant procedures and placements
Funding Insights of Occlutech
Occlutech has successfully raised a total of $70.81M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $49.19 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series C — $49.2M
-
First Round
First Round
(24 Aug 2011)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2021 | Amount | Series C - Occlutech | Valuation | Carnegie , Fjarde AP-fonden |
|
| Aug, 2011 | Amount | Series B - Occlutech | Valuation | unknown |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Occlutech
Occlutech has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Carnegie, Fjarde AP-fonden and unknown. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Financial services are provided by Carnegie in investment and private banking.
|
Founded Year | Domain | Location | |
|
Manages Swedish national pension assets with sustainable investment strategies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Occlutech
Occlutech has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include NonWoTecc Medical. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Vascular prostheses are developed for peripheral and coronary applications.
|
2007 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Occlutech
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Occlutech Comparisons
Competitors of Occlutech
Occlutech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Xeltis, PECA Labs, Endonovo Therapeutics, Coherex and CoAptus Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of bioabsorbable synthetic heart valves and vascular grafts
|
|
| domain | founded_year | HQ Location |
Pediatric cardiac surgical devices are developed for congenital heart defects.
|
|
| domain | founded_year | HQ Location |
Bioelectronic devices are developed for regenerative medicine therapies.
|
|
| domain | founded_year | HQ Location |
Structural heart disease conditions are addressed with implant devices.
|
|
| domain | founded_year | HQ Location |
Develops non-implant therapeutics for treating patent foramen ovale, a structural heart defect.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Occlutech
Frequently Asked Questions about Occlutech
When was Occlutech founded?
Occlutech was founded in 2003 and raised its 1st funding round 8 years after it was founded.
Where is Occlutech located?
Occlutech is headquartered in Schaffhausen, Switzerland. It is registered at Schaffhausen, Schaffhausen, Switzerland.
Who is the current CEO of Occlutech?
Tor Peters is the current CEO of Occlutech. They have also founded this company.
Is Occlutech a funded company?
Occlutech is a funded company, having raised a total of $70.81M across 2 funding rounds to date. The company's 1st funding round was a Series B of $21.62M, raised on Aug 24, 2011.
What does Occlutech do?
Occlutech was founded in 2003 in Schaffhausen, Switzerland, within the cardiovascular medical devices sector. Devices for minimally invasive treatments of congenital heart defects, stroke prevention, and heart failure are developed and supplied. These include ASD occluders, cardiac implants, and accessories targeted at conditions such as Atrial Septal Defect, Patent Foramen Ovale, Left Atrial Appendage closure, Patent Ductus Arteriosus, and paravalvular leaks. Operations focus on structural heart interventions across global markets.
Who are the top competitors of Occlutech?
Occlutech's top competitors include Xeltis, PECA Labs and Endonovo Therapeutics.
What products or services does Occlutech offer?
Occlutech offers Occluders, ATRIAL FLOW REGULATOR, and Accessories.
How many acquisitions has Occlutech made?
Occlutech has made 1 acquisition, including NonWoTecc Medical.
Who are Occlutech's investors?
Occlutech has 3 investors. Key investors include Carnegie, Fjarde AP-fonden, and unknown.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.